Pooranee K. Morgan

Pooranee K. Morgan

Auto-generated profile, based on publicly available information

Pooranee K. Morgan

Baker Heart and Diabetes Institute

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2024 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
PMPooranee K. Morgan
Pooranee K. Morgan
GPGerard Pernes
Gerard Pernes
KHKevin Huynh
Kevin Huynh
CGCorey Giles
Corey Giles
SPSudip Paul
Sudip Paul
AMAndrew Murphy
Andrew Murphy

31 December 2024 in Cardiovascular Research
Verified
Journal Article
Closed access
SJSwetha Jinson
Swetha Jinson
ZZZiyang Zhang
Ziyang Zhang
GLGraeme I Lancaster
Graeme I Lancaster
AMAndrew Murphy
Andrew Murphy
PMPooranee K Morgan
Pooranee K Morgan
Oxidation of lipids, excessive cell death, and iron deposition are prominent features of human atherosclerotic plaques. While extensive research has established the detrimental roles of lipid oxidation and apoptosis in atherosclerosis development, the involvement of iron in atherogenesis is not yet fully understood. With the emergence of an iron-dependent form of cell death termed ferroptosis, new attention has been brought to the complex inter-play among iron, ferroptosis, and atherosclerosis. Mechanistically, ferroptosis is caused by the lethal accumulation of iron-mediated lipid peroxides. Emerging studies have underscored ferroptosis as a contributor to worsened atherosclerosis. Herein, we review the evidence that oxidative damage and iron overload in the context of atherosclerosis may promote ferroptosis within plaques. Furthermore, we summarize recent findings of lipid peroxidation, thereby potentially ferroptosis, in various plaque cell types—such as endothelial cells, macrophages, dendritic cells, T cells, and vascular smooth muscle cells—across different stages of atherosclerosis. Understanding how these processes influence atherosclerotic plaque progression may permit targeting stage-dependent ferroptosis in each cell population and could provide a rationale for developing cell type–specific intervention strategies to mitigate atherogenic ferroptosis effectively.

12 August 2024 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
TCThomas J. C. Collins
Thomas J. C. Collins
PMPooranee K. Morgan
Pooranee K. Morgan
KMKevin Man
Kevin Man
GLGraeme I. Lancaster
Graeme I. Lancaster
AMAndrew Murphy
Andrew Murphy

13 March 2025 in Blood
Verified
Journal Article
Closed access
PMPooranee K. Morgan
Pooranee K. Morgan
AMAndrew J. Murphy
Andrew J. Murphy

30 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSabrina Sofia Burgener
Sabrina Sofia Burgener
MMMark Thomas Milner
Mark Thomas Milner
SDShoumit Dey
Shoumit Dey
PMPooranee K. Morgan
Pooranee K. Morgan
BDBlackmore Daniel
Blackmore Daniel
KSKate Schroder
Kate Schroder
Summary: Signal shutdown mechanisms must exist to silence the potent inflammatory programs initiated by the caspase-1 (CASP1) protease, to allow inflammation to resolve and reinstate tissue homeostasis. It is unknown how CASP1 terminates its activity in vivo . Here, we use a knock-in mouse model in which the CASP1 CARD domain linker (CDL) is mutated to prevent self-cleavage ( Casp1.CDL mice) to show that CASP1 CDL autoproteolysis terminates CASP1 activity in vivo . We examined these mice under homeostatic conditions and in response to major physiological challenges. In the brain, CASP1 CDL mutation caused anxiety-like behaviour under homeostatic conditions, and exacerbated hippocampal spatial learning deficits in the APP23 genetic model of amyloid-induced neurodegeneration. In the bone marrow, CASP1 CDL mutation promoted steady-state granulopoiesis. In a model of diet-induced liver disease, CASP1 CDL mutation accelerated liver steatosis and promoted liver immune cell infiltration, inflammation and damage. In a liver healing model, CASP1 CDL mutation delayed disease resolution, indicating that CASP1 autocleavage is required to restore homeostasis after a major challenge to organ function. Our data reveal that CASP1 CDL self-cleavage terminates CASP1 inflammatory programs in vivo to maintain homeostasis in steady-state, restore homeostasis after a major challenge to organ function, and suppress inflammasome-driven diseases. These data identify CASP1 as a prime anti-inflammatory drug target, as CASP1 inhibitors may enforce homeostasis and prevent inflammasome-driven diseases.

23 April 2026 in Immunology & Cell Biology
Verified
Journal Article
Closed access
PMPooranee K Morgan
Pooranee K Morgan
AMAndrew Murphy
Andrew Murphy